Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial

C. Bourgier 1, 2 S. Kerns 3 S. Gourgou 2 C. Lemanski 2 M. Gutowski 2 P. Fenoglietto 2 G. Romieu 2 N. Crompton 4 J. Lacombe 1, 2 A. Pelegrin 2, 1 M. Ozsahin 5 B. Rosenstein 6 D. Azria 1, 2, *
* Auteur correspondant
1 IRCM - U1194 Inserm - UM - Institut de Recherche en Cancérologie de Montpellier
2 ICM - Institut du Cancer de Montpellier
3 URMC - University of Rochester Medical Center
4 Van Andel Institute [Grand Rapids]
5 CHUV - Centre Hospitalier Universitaire Vaudois [Lausanne]
6 NYU - New York University School of Medicine
Abstract : BACKGROUND: We present here final clinical results of the COHORT trial and both translational sub-studies aiming at identifying patients at risk of radiation-induced subcutaneous fibrosis (RISF): (i) radiation-induced lymphocyte apoptosis (RILA) and (ii) candidates of certain single-nucleotide polymorphisms (SNPs). PATIENTS AND METHODS: Post-menopausal patients with stage I-II breast cancer (n = 150) were enrolled and assigned to either concurrent (arm A) or sequential radiotherapy (RT)-letrozole (arm B). Among them, 121 were eligible for RILA and SNP assays. Grade ≥2 RISF were the primary end point. Secondary end points were lung and heart events and carcinologic outcome. RILA was performed to predict differences in RISF between individuals. A genome-wide association study was performed to identify SNPs associated with RILA and RISF. Analyses were done by intention to treat. RESULTS: After a median follow-up of 74 months, 5 patients developed a grade ≥2 RISF. No significant difference was observed between arms A and B. Neither grade ≥2 lung nor symptomatic cardiac toxicity was observed. Median RILA value of the five patients who had grade ≥2 RISF was significantly lower compared with those who developed grade ≤1 RISF (6.9% versus 13%, P = 0.02). Two SNPs were identified as being significantly associated with RILA: rs1182531 (P = 4.2 × 10(-9)) and rs1182532 (P = 3.6 × 10(-8)); both located within the PHACTR3 gene on chromosome 20q13.33. CONCLUSIONS: With long-term follow-up, letrozole can safely be delivered concomitantly with adjuvant breast RT. Translational sub-studies showed that high RILA values were correlated with patients who did not develop RISF. REGISTERED CLINICAL TRIAL: NCT00208273.
Keywords : breast cancer radiation-induced late effects radio-hormonotherapy
Type de document :
Article dans une revue
Liste complète des métadonnées
https://hal.umontpellier.fr/hal-02338912
Contributeur : Amandine Michel-Avella <>
Soumis le : mercredi 30 octobre 2019 - 10:56:51
Dernière modification le : jeudi 31 octobre 2019 - 01:28:46

Lien texte intégral

pubmedcentral

Identifiants

Collections

UNIV-MONTPELLIER | VALDAURELLE | FNCLCC | BS | IRCM

Citation

C. Bourgier, S. Kerns, S. Gourgou, C. Lemanski, M. Gutowski, et al.. Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial. Annals of Oncology, Oxford University Press (OUP), 2016, 27 (3), pp.474-480. ⟨10.1093/annonc/mdv602⟩. ⟨hal-02338912⟩

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

12